Eidos Therapeutics, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2018. For the quarter, the company reported loss from operations of USD 10,705,000 compared to USD 5,111,000 a year ago. Net loss attributable to common stockholders was USD 9,854,000 compared to USD 5,111,000 a year ago. Net loss per share attributable to common stockholders was USD 0.27 against USD 1.32 a year ago. For the full year, the company reported loss from operations of USD 37,779,000 compared to USD 12,016,000 a year ago. Net loss attributable to common stockholders was USD 39,812,000 compared to USD 11,941,000 a year ago. Net loss per share attributable to common stockholders was USD 1.86 against USD 3.32 a year ago.